Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A safety review of the HER2CLIMB trial reveals that the tucatinib, trastuzumab, and capecitabine (TTC) combo is effective but comes with notable side effects. Diarrhea was the top reason for dose changes, and liver enzyme elevations were more common in the tucatinib arm. Experts say early patient counseling and proactive management can help keep patients on treatment longer.
A detailed safety analysis of the tucatinib, trastuzumab, and capecitabine (TTC) regimen — FDA-approved since 2020 for HER2+ metastatic breast cancer (mBC) — has been published in The Oncologist, drawing on data from the HER2CLIMB trial. The review highlights that while TTC is a preferred option in the third-line setting (or second-line with brain metastases), it carries a meaningful side effect burden that requires proactive management.
Diarrhea emerged as the leading cause of dose modifications, prompting investigators to recommend early patient counseling on dietary habits, probiotics, and antidiarrheals. Elevated liver enzymes were also notably more common in the tucatinib arm, though hepatic side effects were generally manageable and reversible.
By the Numbers:
Why it matters: For oncology teams, these findings underscore the importance of early, open conversations with patients about side effects. Catching and managing AEs quickly can help patients stay on a regimen that may be extending their lives.
